24.05.2013 - Hungary and Poland will cooperate to create a biotech cluster with global reach.
On the first day of the Bioforum conference in Budapest, the heads of the Polish and Hungarian biotech associations signed a cooperation agreement aimed at creating a joint cluster. „Hungary and Poland separately are not able to build an effective and strong business cluster for the biotech sector,“ said Erno Duda, President of the Hungarian Biotech Association (HBA). „After having signed this cooperation agreement we have a great chance to create such a cluster, which will develop in scale of international biotech market and, at the same time, will support local initiative and start-ups.“ Tadeusz Pietrucha, who heads the recently launched Polish Biotech Association (PBA) added: „The global biotech market is hard to reach for small and medium companies from the CEE region. Therefore, we have to cooperate to show our potential in…the biotech world”.
The agreement summarises the most pressing needs of the life sciences sector in both nations but also in the whole Central and Eastern Europe (CCE) region. Both associations will join their forces and their member companies’ skills to attract more national funding and EU grants as well as international collaborators from the biotech and pharmaceutical sector. The plan is supported by their national governments, represented by Grazyna Henclewska, undersecretary of Polish Ministry of Economy and by Zoltán Cséfalvay, vice-minister of Hungarian National Economy, at the conference.
Biotechnology plays an increasing role in the CEE countries. While the sector is young, it is growing and has a strong science base, with biosimilar drug developers, clinical and contract research organisations, and life sciences research companies. Most recently, IBM signed an agreement with Poland’s new Centre for Pre-clinical Research and Technology (CePT), a €100m EU investment aimed at pooling researcher know-how from three universities and seven research institutes to create a fully integrated drug discovery and diagnostics value chain.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.